Unknown

Dataset Information

0

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.


ABSTRACT: Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-CD7 CAR-T cells using endoplasmic reticulum retention have shown efficacy in patients with T-cell acute lymphoblastic leukemia (ALL). Here we launched a phase I trial to explore differences between autologous and allogeneic anti-CD7 CAR-T therapies in T-cell ALL and lymphoma. Ten patients were treated and 5 received autologous CAR-T therapies. No dose-limiting toxicity or neurotoxicity was observed. Grade 1-2 cytokine release syndrome occurred in 7 patients, and grade 3 in 1 patient. Grade 1-2 graft-versus-host diseases were observed in 2 patients. Seven patients had bone marrow infiltration, and 100% of them achieved complete remission with negative minimal residual disease within one month. Two-fifths of patients achieved extramedullary or extranodular remission. The median follow-up was 6 (range, 2.7-14) months and bridging transplantation was not administrated. Patients treated with allogeneic CAR-T cells had higher remission rate, less recurrence and more durable CAR-T survival than those receiving autologous products. Allogeneic CAR-T cells appeared to be a better option for patients with T-cell malignancies.

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC10125858 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.

Zhang Yinqiang Y   Li Chenggong C   Du Mengyi M   Jiang Huiwen H   Luo Wenjing W   Tang Lu L   Kang Yun Y   Xu Jia J   Wu Zhuolin Z   Wang Xindi X   Huang Zhongpei Z   Zhang Yanlei Y   Wu Di D   Chang Alex H AH   Hu Yu Y   Mei Heng H  

Blood cancer journal 20230425 1


Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-CD7 CAR-T cells using endoplasmic reticulum retention have shown efficacy in patients with T-cell acute lymphoblastic leukemia (ALL). Here we launched a phase I trial to explore differences between autologous and allogeneic anti-CD7 CAR-T therapies in T-cell  ...[more]

Similar Datasets

2023-03-25 | GSE227828 | GEO
| PRJNA947149 | ENA
| S-EPMC9652391 | biostudies-literature
2022-09-08 | GSE192453 | GEO
| S-EPMC9523980 | biostudies-literature
| S-EPMC9578248 | biostudies-literature
| S-EPMC9840107 | biostudies-literature
| S-EPMC7655020 | biostudies-literature